Company: HCWB
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0000950170-25-046724
Chunk: 6

Company: HCW Biologics Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1
Chunk 6
---
 one of the most potent immunostimulatory agents we have developed during our team members’ 30 years of biotech research.  Additional studies are being conducted to verify that HCW11-006 should combine well with other therapies, including immune checkpoint inhibitors, immune cell engagers, therapeutic antibodies, and CAR-T therapies, which the Company is conducting with world leaders in these areas.  The Company and collaborators intend to share their findings in a pivotal scientific paper published in a top-tier peer-reviewed journal.    

5 

Other Preclinical Programs

Our future clinical development will focus on our T-cell Receptor β Chain constant region  (“TRBC”) drug discovery and development platform.  The Company has constructed over 50 compounds using the TRBC platform, which we group into three different classes, as defined by their construction and potential mechanism of action.  We are in the process of selecting lead compounds for each program, and then to determine from the compounds selected which ones we will develop on our own and those we will develop with a partner through out-licensing arrangements or other business development transactions.  

The table below summarizes our preclinical programs by classes:    

Preclinical TRBC-Based Molecules Drug Development Programs

    Classes
    Description of Programs 

    I
    Multi-functional immune cell stimulators•HCW11-006 is the selected lead product candidate for this class.•Potent immunostimulatory agent to use in combination with standard-of-care therapy.•Preclinical studies in human immune cells animal models demonstrate HCW11-006 is highly effective at inducing CD8+ T cell and NK cell responses without triggering unwanted side effects.•HCW11-006 also exhibits anti-tumor efficacy in relevant solid tumor animal models.•Prioritized for development through exclusive, worldwide license with WY Biotech. 

    II
    Second-generation immune checkpoint inhibitors•We have a group of compounds in this class and are currently assessing them in order to identify the strongest candidate for clinical development.  •Developing a second-generation Keytruda® for oncology & other senescence associated indications.  •Prioritized for in-house development. 

    III
    Multi-specific targeting fusions and immune cell engagers•Class III TRBC Molecules are second-generation immune-cell engagers capable of targeting tissue factor and other cell-surface antigens associated with diseased cells.  These drugs work by recruiting and activating T-cells or NK cells, types of white blood cell, to recognize and attack cancer cells.  •Our